Respiratory Analytics Ltd

**Over 400M live with asthma globally - 30M in Europe and 26M in the US**. **UK asthma mortality is the worst in Europe**. Globally, **annual costs exceed $363B**, **driven by 'uncontrolled asthma'**. In the **UK there are 5.4M asthmatics with a total cost to the economy of over £22B/ year**. **Only 1.8% of public research spend** goes toward lung conditi...

**Globally asthma is the most common non-communicable disease in children,** with about 10-15% having asthma symptoms in the last year. Inhaled medication is the mainstay of treatment but **inhaler technique errors amongst all users and all devices are highly prevalent**. Evidence shows **high asthma prevalence in children in the UK with 1.1 million child...

Globally, more than 750M people live with asthma and chronic obstructive pulmonary disease (COPD). Uncontrolled symptoms of these conditions cost $34B in the US and £1.5B in the UK annually. Pressurised metered-dose inhalers (MDIs) were introduced in 1956 for the treatment of asthma and COPD, followed by Dry Powder Inhalers (DPIs) in the 1980's. Evidence ...

Over 325M people around the world - and 5.4M in the UK - suffer from asthma, costing over $363B every year. Rising health inequalities, the coronavirus pandemic, growing patient burden and costs demand better asthma management. The correct use of inhaler devices and adherence to prescribed therapy are essential for optimal control, avoiding exacerbations,...

The global cost of asthma is high and rising with an expected 400M sufferers by 2025 and 1000 deaths every day. The UK has one of the highest prevalence and mortality rates in Europe. Over 5.4 million people in the UK have this complex condition which is often difficult to manage. Around 1400 people die each year in the UK and up to 70% of these deaths ar...